Tirzepatide: A Novel, Once-weekly Dual GIP and GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes
Endocrinology · 2022
DOI: 10.17925/ee.2022.18.1.10 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Endocrinology, 2022. Verfasst von Shizuka Kaneko. Beteiligte Einrichtung: Division of Diabetes/Endocrinology/Lifestyle-Related Disease, Takatsuki Red Cross Hospital, Takatsuki, Japan. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 88 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: This article is published under the Creative Commons Attribution Non-commercial License..
Themen: Diabetes mellitus
Abstract (Originalsprache)
Gastrointestinal hormones are currently used to treat type 2 diabetes mellitus (T2D). Incretin preparations with gastric inhibitory polypeptide (GIP) activity or glucagon-like peptide-1 (GLP-1) provide new means for controlling blood glucose levels, body weight, and lipid metabolism. GIP, an incretin, has not been used due to lack of promising action against diabetes. However, recent studies have shown that GIP has an important effect on glucagon and insulin secretion under normoglycaemic conditions. Co-existence of GIP with GLP-1 and glucagon signalling leads to a stronger effect than that of GLP-1 stimulation alone. The development of a GIP/GLP-1R unimolecular dual agonist with affinity for both GIP and GLP-1 receptors is under investigation, and the drug is expected to be clinically available in the near future. Tirzepatide, a GIP/GLP-1R unimolecular dual agonist, regulates metabolism via both peripheral organs and the central nervous system. The SURPASS phase III clinical trials conducted for tirzepatide comprise 10 clinical trials, including five global trials and the global SURPASS-CVOT trial, with >13,000 patients with T2D (ClinicalTrials.gov Identifier: NCT04255433). The clinical application of tirzepatide as a therapy for T2D may provide new insights into diabetic conditions and help clarify the role of GIP in its pathogenesis.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Diabetes/Endocrinology/Lifestyle-Related Disease, Takatsuki Red Cross Hospital, Takatsuki, Japan.
Förderung
- This article is published under the Creative Commons Attribution Non-commercial License.
Zitieren
APA
Kaneko, S. (2022). Tirzepatide: A Novel, Once-weekly Dual GIP and GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes. Endocrinology. https://doi.org/10.17925/ee.2022.18.1.10
Vancouver
Kaneko S. Tirzepatide: A Novel, Once-weekly Dual GIP and GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes. Endocrinology. 2022. doi:10.17925/ee.2022.18.1.10
BibTeX
@article{Kaneko2022,
author = {Kaneko, Shizuka},
title = {Tirzepatide: A Novel, Once-weekly Dual GIP and GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes},
journal = {Endocrinology},
year = {2022},
doi = {10.17925/ee.2022.18.1.10}
}
EUVIMED